The Pharmacy Times® Chronic Obstructive Pulmonary Disease (COPD) Disease Resource Center is a comprehensive resource for clinical news and expert insights on a group of diseases that cause airflow blockage and breathing-related problems, including emphysema and chronic bronchitis.
April 2nd 2024
The Asthma and Allergy Foundation of America applauded the efforts by AstraZeneca, saying accessibility and affordability can help reduce racial disparities in asthma.
Evolving Treatment Strategies in the Management of Pulmonary Arterial Hypertension: Key Insights for the Pharmacist, featuring a Patient Perspective
1.5 Credits / Pulmonology/Respiratory
View More
Advances in EGFR Exon 20 Insertion-Positive Non–Small Cell Lung Cancer: A Focus on Specialty Pharmacy Interventions
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Exploring Recent Advances in the Treatment of COPD: An Update for Pharmacists
0.75 Credit / Pulmonology/Respiratory
View More
Novel Therapeutic Approaches for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer: An Oncology Pharmacy Perspective
1.0 Credit / Oncology, Pulmonology/Respiratory
View More
Practical Approaches in the Management of Pulmonary Arterial Hypertension: Understanding the Pharmacist’s Role in Personalized Care
1.0 Credit / Pulmonology/Respiratory
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Advances and Best Practices for Managed Care Pharmacists and the Treatment of Patients with Alpha-1 Antitrypsin Deficiency
1.0 Credit / Pulmonology/Respiratory
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Integrating Guideline-Driven Protocols Into Evidence-Based Practice to Improve Outcomes in Patients With Pulmonary Arterial Hypertension
1.0 Credit / Respiratory
View More
GASp, Where’s the Amoxicillin? Group A Streptococcus Infections and What Pharmacists Need to Know
1.0 Credit / Pulmonology/Respiratory
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Exploring the GOLD Report Updates and the Value of Patient-Centered Strategies for the Treatment of Chronic Obstructive Pulmonary Disease: Opportunities to Reduce Health Burde...
1.0 Credit / Pulmonology/Respiratory
View More
Exploring the GOLD Report Updates and the Value of Patient-Centered Strategies for the Treatment of Chronic Obstructive Pulmonary Disease: Opportunities to Reduce Health Burde...
1.0 Credit / Pulmonology/Respiratory
View More
COVID-19 Has Devastating Effects for Patients Suffering From COPD
While the prevalence of COVID-19 in patients with COPD is relatively low, those who are infected with the virus experience more severe symptoms than those without COPD.
Read More
2020 Vaccination Recommendations for Patients With Chronic Medical Conditions
November 27th 2020In the midst of the COVID-19 pandemic, it is important that individuals who are at higher risk for poor outcomes from infection with vaccine-preventable diseases remain up-to-date with their immunizations.
Read More
FDA Approves Fluticasone Furoate, Umeclidinium, Vilanterol for Treatment of Asthma
September 14th 2020The triple combination therapy is the first single inhaler triple therapy approved for both asthma and COPD and is the only single inhaler triple therapy available as a once-daily inhalation.
Read More
FDA Approves Budesonide/Glycopyrrolate/Formoterol Fumarate for Treatment of Patients With COPD
July 24th 2020Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere, AstraZeneca) has been approved by the FDA for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), according to a press release.
Read More
Investigators Propose Tool for Managing COPD and Use of Inhaled Corticosteroids
January 23rd 2020Investigators have proposed a tool involving a personalized approach for managing chronic obstructive pulmonary disease (COPD) and the use of inhaled corticosteroids (ICS), according to the results of a recent study published in the International Journal of Chronic Obstructive Pulmonary Disease.
Read More
Class of Cancer Drugs May Have Potential as Chronic Obstructive Pulmonary Disease Treatment
January 17th 2020The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.
Read More
Digital Health Tool Improves Health Outcomes for Patients with COPD
November 27th 2019The tool, which works by attaching a small sensor to the patient’s inhaler, collects data on medication use and sends medication reminders, progress reports, and disease insights to the patient’s smartphone or hub.
Read More
Studies Test Revefenacin Safety, Efficacy in Patients with COPD
October 23rd 2019Results from the safety and efficacy trial of revefenacin (REV) demonstrated that the drug had a safety profile similar to foremoterol (FOR). In addition, patients with COPD in the suboptimal peak inspiratory flow rate trial (sPIFR) showed lower weight, BMI, and lung function in comparison to patients with optimal peak inspiratory flow rate (oPIFR) in a second study.
Read More
Researcher Awarded $7.5 Million in Funding for COPD Research
October 13th 2019A researcher at the Washington University School of Medicine in St.Louis has received close to $7.5 million in total funding for research towards development of stem cell-based treatments for chronic pulmonary disease (COPD), asthma, and other disorders.
Read More
Triple Combination Therapy Shows Positive Results for Patients with COPD
September 5th 2019The Phase III ETHOS trial for AstraZeneca's budesonide, glycopyrronium and formoterol fumarate, 320/14.4/9.6mcg (Breztri Aerosphere) combination therapy has demonstrated positive results for patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Read More
Increased COPD Prevalence Linked with Arthritis
July 26th 2019A recent study found the prevalence of COPD was nearly 50% higher among patients with arthritis compared with those without arthritis, even after adjusting for sociodemographic characteristics, risk behaviors, frequent distress, and asthma status.
Read More